{"id":483408,"date":"2020-05-08T18:42:02","date_gmt":"2020-05-08T18:42:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=483408"},"modified":"2020-05-08T18:42:02","modified_gmt":"2020-05-08T18:42:02","slug":"duchenne-muscular-dystrophy-pipeline-insights-2020","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/duchenne-muscular-dystrophy-pipeline-insights-2020_483408.html","title":{"rendered":"Duchenne Muscular Dystrophy &#8211; Pipeline Insights, 2020"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Duchenne Muscular Dystrophy - Pipeline Insights, 2020\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Duchenne Muscular Dystrophy - Pipeline Insights, 2020\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Duchenne Muscular Dystrophy Pipeline Insight, 2020&#8243; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Duchenne Muscular Dystrophy market. <\/div>\n<p style=\"text-align: justify;\"><strong>Duchenne Muscular Dystrophy Pipeline Insight<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Duchenne Muscular Dystrophy&nbsp;Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">&#8220;Duchenne Muscular Dystrophy Pipeline Insight, 2020&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the&nbsp;Duchenne Muscular Dystrophy&nbsp;market. A detailed picture of the&nbsp;Duchenne Muscular Dystrophy&nbsp;pipeline landscape is provided, which includes the disease overview and&nbsp;Duchenne Muscular Dystrophy&nbsp;treatment guidelines. The assessment part of the report embraces in-depth&nbsp;Duchenne Muscular Dystrophy&nbsp;commercial assessment and clinical assessment of the&nbsp;Duchenne Muscular Dystrophy&nbsp;pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology,&nbsp;Duchenne Muscular Dystrophy&nbsp;collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Duchenne Muscular Dystrophy of&nbsp;pipeline development activities&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">The report provides insights into:&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>All of the companies that are developing therapies for the treatment of&nbsp;Duchenne Muscular Dystrophy&nbsp;with aggregate therapies developed by each company for the same.<\/li>\n<li>Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the&nbsp;Duchenne Muscular Dystrophy&nbsp;treatment.<\/li>\n<li>Duchenne Muscular Dystrophy&nbsp;key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of&nbsp;Duchenne Muscular Dystrophy&nbsp;market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university web sites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Duchenne Muscular Dystrophy&nbsp;Analytical Perspective by DelveInsight<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>In-depth Duchenne Muscular Dystrophy Commercial Assessment of products&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing\/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.<\/p>\n<ul style=\"text-align: justify;\">\n<li>Duchenne Muscular Dystrophy Clinical Assessment of products&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The&nbsp;Duchenne Muscular Dystrophy&nbsp;report provides an overview of&nbsp;<em>therapeutic pipeline activity and therapeutic assessment of the products<\/em>&nbsp;by development stage, product type, route of administration, molecule type, and MOA type&nbsp;<em>for&nbsp;<\/em>Duchenne Muscular Dystrophy&nbsp;across the complete product development cycle, including all clinical and nonclinical stages.<\/li>\n<li>It comprises of&nbsp;<em>detailed profiles of&nbsp;<\/em>Duchenne Muscular Dystrophy&nbsp;<em>therapeutic products<\/em>&nbsp;with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details<\/li>\n<li>Detailed&nbsp;Duchenne Muscular Dystrophy&nbsp;<em>research and development progress and trial details<\/em>, results wherever available, are also included in the pipeline study.<\/li>\n<li><em>Coverage of dormant and discontinued pipeline project<\/em>s along with the reasons if available across&nbsp;Duchenne Muscular Dystrophy.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/duchenne-muscular-dystrophy-pipeline-insight\"><strong>Request for sample pages<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Report highlights<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>A better understanding of disease pathogenesis contributing to the development of novel therapeutics for&nbsp;Duchenne Muscular Dystrophy.&nbsp;&nbsp;&nbsp;&nbsp;<\/li>\n<li>In the coming years, the&nbsp;Duchenne Muscular Dystrophy&nbsp;market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.&nbsp;<\/li>\n<li>The companies and academics that are working to assess challenges and seek opportunities that could influence&nbsp;Duchenne Muscular Dystrophy&nbsp;R&amp;D. The therapies under development are focused on novel approaches to treat\/improve the disease condition.<\/li>\n<li>A detailed portfolio of major pharma players who are involved in fueling the&nbsp;Duchenne Muscular Dystrophy&nbsp;treatment market. Several potential therapies for&nbsp;Duchenne Muscular Dystrophy&nbsp;are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the&nbsp;Duchenne Muscular Dystrophy&nbsp;market size in the coming years.&nbsp;&nbsp;<\/li>\n<li>Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of&nbsp;Duchenne Muscular Dystrophy) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Questions<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>What are the current options for&nbsp;Duchenne Muscular Dystrophy&nbsp;treatment?<\/li>\n<li>How many companies are developing therapies for the treatment of&nbsp;Duchenne Muscular Dystrophy?&nbsp;<\/li>\n<li>What are the principal therapies developed by these companies in the industry?<\/li>\n<li>How many therapies are developed by each company for the treatment of&nbsp;Duchenne Muscular Dystrophy?<\/li>\n<li>How many&nbsp;Duchenne Muscular Dystrophy&nbsp;emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of&nbsp;Duchenne Muscular Dystrophy?<\/li>\n<li>Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?&nbsp;<\/li>\n<li>What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact&nbsp;Duchenne Muscular Dystrophy&nbsp;market?&nbsp;<\/li>\n<li>Which are the dormant and discontinued products and the reasons for the same?<\/li>\n<li>What is the unmet need for current therapies for the treatment of&nbsp;Duchenne Muscular Dystrophy?&nbsp;&nbsp;<\/li>\n<li>What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing&nbsp;Duchenne Muscular Dystrophy&nbsp;therapies?&nbsp;<\/li>\n<li>What are the clinical studies going on for&nbsp;Duchenne Muscular Dystrophy&nbsp;and their status?<\/li>\n<li>What are the results of the clinical studies and their safety and efficacy?&nbsp;<\/li>\n<li>What are the key designations that have been granted for the emerging therapies for&nbsp;Duchenne Muscular Dystrophy?&nbsp;<\/li>\n<li>How many patents are granted and pending for the emerging therapies for the treatment of&nbsp;Duchenne Muscular Dystrophy?&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Table of contents&nbsp;<\/p>\n<p style=\"text-align: justify;\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Duchenne Muscular Dystrophy&nbsp;<\/p>\n<p style=\"text-align: justify;\">2.1. Overview<\/p>\n<p style=\"text-align: justify;\">2.2. History&nbsp;<\/p>\n<p style=\"text-align: justify;\">2.3. Duchenne Muscular Dystrophy Symptoms<\/p>\n<p style=\"text-align: justify;\">2.4. Causes<\/p>\n<p style=\"text-align: justify;\">2.5.Pathophysiology<\/p>\n<p style=\"text-align: justify;\">2.6. Duchenne Muscular Dystrophy Diagnosis&nbsp;<\/p>\n<p style=\"text-align: justify;\">2.6.1. Diagnostic Guidelines<\/p>\n<p style=\"text-align: justify;\">3. Duchenne Muscular Dystrophy&nbsp;Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\">3.1. Duchenne Muscular Dystrophy Treatment Guidelines<\/p>\n<p style=\"text-align: justify;\">4. Duchenne Muscular Dystrophy&nbsp;&#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">4.1. In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">4.1.1. Duchenne Muscular Dystrophy&nbsp;companies collaborations, Licensing, Acquisition -Deal Value Trends<\/p>\n<p style=\"text-align: justify;\">4.1.1.1. Assessment Summary<\/p>\n<p style=\"text-align: justify;\">4.1.2. Duchenne Muscular Dystrophy&nbsp;Collaboration Deals<\/p>\n<p style=\"text-align: justify;\">4.1.2.1. Company-Company Collaborations (Licensing \/ Partnering) Analysis<\/p>\n<p style=\"text-align: justify;\">4.1.2.2. Company-University Collaborations (Licensing \/ Partnering) Analysis<\/p>\n<p style=\"text-align: justify;\">4.1.2.3. Duchenne Muscular Dystrophy&nbsp;Acquisition Analysis<\/p>\n<p style=\"text-align: justify;\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">5.1. Clinical Assessment of Pipeline Drugs&nbsp;<\/p>\n<p style=\"text-align: justify;\">5.1.1. Assessment by Phase of Development<\/p>\n<p style=\"text-align: justify;\">5.1.2. Assessment by Product Type (Mono \/ Combination)<\/p>\n<p style=\"text-align: justify;\">5.1.2.1. Assessment by Stage and Product Type<\/p>\n<p style=\"text-align: justify;\">5.1.3. Assessment by Route of Administration<\/p>\n<p style=\"text-align: justify;\">5.1.3.1. Assessment by Stage and Route of Administration<\/p>\n<p style=\"text-align: justify;\">5.1.4. Assessment by Molecule Type<\/p>\n<p style=\"text-align: justify;\">5.1.4.1. Assessment by Stage and Molecule Type<\/p>\n<p style=\"text-align: justify;\">5.1.5. Assessment by MOA<\/p>\n<p style=\"text-align: justify;\">5.1.5.1. Assessment by Stage and MOA<\/p>\n<p style=\"text-align: justify;\">5.1.6. Assessment by Target<\/p>\n<p style=\"text-align: justify;\">5.1.6.1. Assessment by Stage and Target<\/p>\n<p style=\"text-align: justify;\">6. Duchenne Muscular Dystrophy Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\">7. Duchenne Muscular Dystrophy Mid Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\">12. Duchenne Muscular Dystrophy Discontinued Products<\/p>\n<p style=\"text-align: justify;\">13. Duchenne Muscular Dystrophy&nbsp;Product Profiles<\/p>\n<p style=\"text-align: justify;\">13.1. Drug Name: Company&nbsp;<\/p>\n<p style=\"text-align: justify;\">13.1.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.1.1.1. Product Overview<\/p>\n<p style=\"text-align: justify;\">13.1.1.2. Mechanism of action<\/p>\n<p style=\"text-align: justify;\">13.1.2. Research and Development<\/p>\n<p style=\"text-align: justify;\">13.1.2.1. Clinical Studies<\/p>\n<p style=\"text-align: justify;\">13.1.3. Product Development Activities<\/p>\n<p style=\"text-align: justify;\">13.1.3.1. Collaboration<\/p>\n<p style=\"text-align: justify;\">13.1.3.2. Agreements<\/p>\n<p style=\"text-align: justify;\">13.1.3.3. Acquisition&nbsp;<\/p>\n<p style=\"text-align: justify;\">13.1.3.4. Patent Detail<\/p>\n<p style=\"text-align: justify;\">13.1.4. Tabulated Product Summary<\/p>\n<p style=\"text-align: justify;\">13.1.4.1. General Description Table<\/p>\n<p style=\"text-align: justify;\">Detailed information in the report?&nbsp;<\/p>\n<p style=\"text-align: justify;\">14. Duchenne Muscular Dystrophy&nbsp;Key Companies<\/p>\n<p style=\"text-align: justify;\">15. Duchenne Muscular Dystrophy&nbsp;Key Products<\/p>\n<p style=\"text-align: justify;\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\">16.1. Dormant Products<\/p>\n<p style=\"text-align: justify;\">16.1.1. Reasons for being dormant<\/p>\n<p style=\"text-align: justify;\">16.2. Discontinued Products&nbsp;<\/p>\n<p style=\"text-align: justify;\">16.2.1. Reasons for the discontinuation<\/p>\n<p style=\"text-align: justify;\">17. Duchenne Muscular Dystrophy&nbsp;Unmet Needs<\/p>\n<p style=\"text-align: justify;\">18. Duchenne Muscular Dystrophy&nbsp;Future Perspectives<\/p>\n<p style=\"text-align: justify;\">19. Duchenne Muscular Dystrophy&nbsp;Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\">21.1. Secondary Research<\/p>\n<p style=\"text-align: justify;\">21.2. Expert Panel Validation<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Priya Maurya<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=duchenne-muscular-dystrophy-pipeline-insights-2020\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=duchenne-muscular-dystrophy-pipeline-insights-2020\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Duchenne Muscular Dystrophy Pipeline Insight, 2020&#8243; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Duchenne Muscular Dystrophy market. Duchenne Muscular Dystrophy Pipeline Insight Duchenne Muscular Dystrophy&nbsp;Overview &#8220;Duchenne Muscular Dystrophy Pipeline Insight, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/duchenne-muscular-dystrophy-pipeline-insights-2020_483408.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-483408","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/483408","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=483408"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/483408\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=483408"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=483408"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=483408"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}